Pfizer (NYSE: PFE) and Eli Lilly (NYSE: LLY) have worked together for years on the development of an osteoarthritis pain drug, tanezumab. In this Motley Fool Live video recorded on March 24, 2021 , Motley Fool contributors Keith Speights and Brian Orelli talked about the hurdles the two companies must jump to win U.S. approval for the drug. (Note: A U.S. Food and Drug Administration [FDA] Advisory Committee voted 19-1 against tanezumab on March 25. The FDA has not yet made a final decision on approval of the drug.)
For further details see:
Could Pfizer's and Lilly's Long-Awaited Osteoarthritis Drug Flop?